Objective To explore the clinical effect of Moluodan combined with rebamipide and mosapride in the treatment of patients with chronic atrophic gastritis.Methods 120 cases of patients with chronic atrophic gastritis admitted to our hospital from February 2020 to March 2022 were selected and randomly divided into observation group(n=60)and control group(n=60).The control group was treated with rebamipide combined with mosapride,and the observation group was treated with Moluodan on the basis of the control group.The treatment effect,serum pepsinogen and inflammatory factor levels were compared between the two groups.Results The total effective rate of the treatment in the observation group was 96.67％,significantly higher than 85.00％in the control group(P＜0.05).After treatment,the pepsinogen Ⅰ(PG Ⅰ)of the observation group was significantly higher than that of the control group,and the pepsinogen Ⅱ(PG Ⅱ),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)levels were significantly lower than those of the control group(P＜0.05).Conclusions Moluodan combined with rebamipide and mosapride has significant effect in the treatment of chronic atrophic gastritis,which can significantly improve the levels of serum pepsinogen and inflammatory factors,and is worthy of clinical promotion and application.
国家科技期刊平台
NSTL
万方数据
